Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses
暂无分享,去创建一个
S. Sambhara | Shivaprakash Gangappa | S. Mittal | I. York | Ahmed O. Hassan | O. Amen | Samuel Amoah | S. Vemula | Ekramy E Sayedahmed | Ekramy E. Sayedahmed
[1] W. Cao,et al. A highly immunogenic vaccine against A/H7N9 influenza virus. , 2016, Vaccine.
[2] I. Wilson,et al. Preferential Recognition of Avian-Like Receptors in Human Influenza A H7N9 Viruses , 2013, Science.
[3] K. Subbarao,et al. H5N1 vaccines in humans. , 2013, Virus Research.
[4] H. Son,et al. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response. , 2013, Journal of virological methods.
[5] D. Burke,et al. Limited airborne transmission of influenza A/H7N9 virus between ferrets , 2013, Nature.
[6] Ke Xu,et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation , 2013, BMJ.
[7] Y. Guan,et al. Infectivity, Transmission, and Pathology of Human-Isolated H7N9 Influenza Virus in Ferrets and Pigs , 2013, Science.
[8] Jie Dong,et al. Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .
[9] R. Donis,et al. Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness , 2013, PloS one.
[10] R. Webby,et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study , 2013, The Lancet. Infectious diseases.
[11] K. Kedzierska,et al. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T‐cell responses , 2013, Immunology and cell biology.
[12] F. Kostolanský,et al. Epitope specificity of anti‐HA2 antibodies induced in humans during influenza infection , 2012, Influenza and other respiratory viruses.
[13] R. Hai,et al. Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice , 2012, Journal of Virology.
[14] Theo M Bestebroer,et al. Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets , 2012, Science.
[15] P. Palese,et al. A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo , 2012, Journal of Virology.
[16] R. Donis,et al. Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine , 2012, PloS one.
[17] Gabriele Neumann,et al. Experimental adaptation of an influenza H5 haemagglutinin (HA) confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets , 2012, Nature.
[18] R. Couch,et al. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. , 2011, Vaccine.
[19] F. E. Lee,et al. Antibodies Against Conserved Antigens Provide Opportunities for Reform in Influenza Vaccine Design , 2011, Front. Immun..
[20] A. García-Sastre,et al. Influenza A viruses: new research developments , 2011, Nature Reviews Microbiology.
[21] A. Fauci,et al. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine , 2010, Nature Medicine.
[22] D. Ekiert,et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.
[23] S. Mittal,et al. Production of adenovirus vectors and their use as a delivery system for influenza vaccines , 2010, Expert opinion on biological therapy.
[24] G. Nabel,et al. Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.
[25] R. Varadarajan,et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.
[26] John Steel,et al. Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.
[27] Shibo Jiang,et al. Research and development of universal influenza vaccines. , 2010, Microbes and infection.
[28] R. Vemulapalli,et al. Evaluation of Cross-Reactive Cell-Mediated Immune Responses among Human, Bovine and Porcine Adenoviruses , 2010, Gene Therapy.
[29] C. Bridges,et al. Past, Present, and Possible Future Human Infection with Influenza Virus A Subtype H7 , 2009, Emerging infectious diseases.
[30] Gira Bhabha,et al. Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.
[31] T. Tumpey,et al. The public health impact of avian influenza viruses. , 2009, Poultry science.
[32] W. Fiers,et al. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments , 2009, Expert review of vaccines.
[33] I. Donatelli,et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. , 2009, Vaccine.
[34] P. Tien,et al. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. , 2009, Antiviral research.
[35] J. Shiver,et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. , 2009, Vaccine.
[36] John Sidney,et al. Immunomic Analysis of the Repertoire of T-Cell Specificities for Influenza A Virus in Humans , 2008, Journal of Virology.
[37] W. Fiers,et al. An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2* , 2008, Journal of Biological Chemistry.
[38] Y. Matsuoka,et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. , 2008, The Journal of infectious diseases.
[39] J. Katz,et al. New Pre‐pandemic Influenza Vaccines: An Egg‐ and Adjuvant‐independent Human Adenoviral Vector Strategy Induces Long‐lasting Protective Immune Responses in Mice , 2007, Clinical pharmacology and therapeutics.
[40] Xiaopei Huang,et al. Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent Pathways , 2007, Journal of Virology.
[41] R. Couch,et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] Wentao Gao,et al. Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization , 2006, Journal of Virology.
[43] J. Katz,et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice , 2006, The Lancet.
[44] P. Doherty,et al. Cell-mediated Protection in Influenza Infection , 2006, Emerging infectious diseases.
[45] G. Nabel,et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. , 2005, Vaccine.
[46] S. Mittal,et al. Development of nonhuman adenoviruses as vaccine vectors , 2005, Vaccine.
[47] C. Elmets,et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. , 2005, Vaccine.
[48] M. Kinch,et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1 , 2004, Cancer Gene Therapy.
[49] M. Tang,et al. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. , 2004, Vaccine.
[50] J. Shiver,et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.
[51] W. Fiers,et al. A "universal" human influenza A vaccine. , 2004, Virus research.
[52] Marion Koopmans,et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[53] L. M. Albright. Vectors , 2003, Current protocols in molecular biology.
[54] P. Doherty,et al. Differential Antigen Presentation Regulates the Changing Patterns of CD8+ T Cell Immunodominance in Primary and Secondary Influenza Virus Infections , 2003, The Journal of experimental medicine.
[55] Maria Zambon,et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. , 2003, Vaccine.
[56] A. V. van Olphen,et al. Development and Characterization of Bovine × Human Hybrid Cell Lines That Efficiently Support the Replication of both Wild-Type Bovine and Human Adenoviruses and Those with E1 Deleted , 2002, Journal of Virology.
[57] L. Brown,et al. Induction of Long-Term Memory CD8+ T Cells for Recall of Viral Clearing Responses against Influenza Virus , 2002, Journal of Virology.
[58] M. Zambon,et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.
[59] M. Peiris,et al. Human infection with influenza H9N2 , 1999, The Lancet.
[60] Y. Guo,et al. [Discovery of men infected by avian influenza A (H9N2) virus]. , 1999, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.
[61] F. Graham,et al. High-efficiency Cre/loxp based system for construction of adenovirus vectors , 1999 .
[62] L. Babiuk,et al. Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). , 1995, Virology.
[63] J. Ulmer,et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.
[64] B. Moss,et al. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[65] J. Skehel,et al. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells , 1984, The Journal of experimental medicine.
[66] J. Skehel,et al. Recognition of influenza A virus nucleoprotein by an H-2-restricted cytotoxic T-cell clone. , 1984, Virology.
[67] R. Webster,et al. Localization, synthesis, and activity of an antigenic site on influenza virus hemagglutinin. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[68] C. Dolea,et al. World Health Organization , 1949, International Organization.
[69] H. Frost,et al. The American Journal of Hygiene , 1920, Science.
[70] F. Kostolanský,et al. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. , 2011, Acta virologica.
[71] J. Shiver,et al. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. , 2006, Journal of pharmaceutical sciences.
[72] T. Kuiken,et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[73] W Chen,et al. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. , 2000, Immunity.
[74] T. Teyler. Of Mice and Monkeys. , 1971 .
[75] in in Humans. , 2021 .